Compare Crowdstrike Holdings Inc (CRWD) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crowdstrike Holdings Inc vs Cytokinetics Inc — how do they compare? Crowdstrike Holdings Inc trades at $275.59 (market cap $269.31B), while Cytokinetics Inc trades at $62.69 (market cap $8.62B). The key difference: Crowdstrike Holdings Inc is far larger — about 31.2× Cytokinetics Inc's market cap, and Crowdstrike Holdings Inc is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crowdstrike Holdings Inc for 97 Days and Cytokinetics Inc for 19 Days on average.
| CRWD | CYTK | |
|---|---|---|
Market Cap | $269.31B | $8.62B |
Volume | 9,381,560 | 2,594,626 |
Sector | Technology | Health |
52-Week High | $278.86 | $87.26 |
52-Week Low | $87.56 | $54.76 |
Typical Hold Time | 97 Days | 19 Days |
Enterprise Value | $265.11B | $8.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CrowdStrike (CRWD) trades at $275.04, up 3.62% today and near its all-time high, with a bullish technical signal from moving averages. The company shows strong revenue growth, reaching $3.95B in 2025, though net income remains negative at -$19.27M. Recent earnings beats and positive analyst sentiment (76% buy ratings) highlight momentum, while the stock trades at elevated valuation multiples like P/S of 49.86. Key developments include expansion into the OpenAI Marketplace and AI-driven cybersecurity demand.
Outlook: CrowdStrike's growth trajectory and AI positioning offer upside, but high valuations and profitability challenges pose risks. Analyst consensus target is $235.74, below current price, suggesting caution despite bullish sentiment. Competitive pressures and execution on net income conversion are critical for sustained gains.
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
